DE69423459T2 - Dihydrat des N-(4-Amino-6,7-dimethoxychinazol-2-yl)-N-methyl-N'-(tetrahydrofuroyl-2)-propylendiamin Hydrochlorids(=Alfuzosin Hydrochlorid Dihydrat) und ein Verfahren zur Herstellung - Google Patents

Dihydrat des N-(4-Amino-6,7-dimethoxychinazol-2-yl)-N-methyl-N'-(tetrahydrofuroyl-2)-propylendiamin Hydrochlorids(=Alfuzosin Hydrochlorid Dihydrat) und ein Verfahren zur Herstellung

Info

Publication number
DE69423459T2
DE69423459T2 DE69423459T DE69423459T DE69423459T2 DE 69423459 T2 DE69423459 T2 DE 69423459T2 DE 69423459 T DE69423459 T DE 69423459T DE 69423459 T DE69423459 T DE 69423459T DE 69423459 T2 DE69423459 T2 DE 69423459T2
Authority
DE
Germany
Prior art keywords
dihydrate
hydrochloride
preparation
dimethoxyquinazol
tetrahydrofuroyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69423459T
Other languages
English (en)
Other versions
DE69423459D1 (de
Inventor
Regis Borrega
Satoshi Kitamura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of DE69423459D1 publication Critical patent/DE69423459D1/de
Publication of DE69423459T2 publication Critical patent/DE69423459T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DE69423459T 1993-12-28 1994-12-23 Dihydrat des N-(4-Amino-6,7-dimethoxychinazol-2-yl)-N-methyl-N'-(tetrahydrofuroyl-2)-propylendiamin Hydrochlorids(=Alfuzosin Hydrochlorid Dihydrat) und ein Verfahren zur Herstellung Expired - Lifetime DE69423459T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP5353828A JPH07206857A (ja) 1993-12-28 1993-12-28 アルフゾシン塩酸塩の二水和物

Publications (2)

Publication Number Publication Date
DE69423459D1 DE69423459D1 (de) 2000-04-20
DE69423459T2 true DE69423459T2 (de) 2000-10-26

Family

ID=18433498

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69423459T Expired - Lifetime DE69423459T2 (de) 1993-12-28 1994-12-23 Dihydrat des N-(4-Amino-6,7-dimethoxychinazol-2-yl)-N-methyl-N'-(tetrahydrofuroyl-2)-propylendiamin Hydrochlorids(=Alfuzosin Hydrochlorid Dihydrat) und ein Verfahren zur Herstellung

Country Status (6)

Country Link
US (1) US5545738A (de)
EP (1) EP0663398B1 (de)
JP (1) JPH07206857A (de)
KR (1) KR100329156B1 (de)
AT (1) ATE190614T1 (de)
DE (1) DE69423459T2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0849265A1 (de) * 1996-12-20 1998-06-24 HEUMANN PHARMA GmbH Neue polymorphe Form von Doxazosin-Mesylat (Form II)
GB9708917D0 (en) * 1997-05-01 1997-06-25 Pfizer Ltd Compounds useful in therapy
DE19951418A1 (de) * 1999-10-26 2001-05-03 Merck Patent Gmbh Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid
DE10232113A1 (de) * 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
PL1789412T3 (pl) * 2004-09-16 2008-10-31 Hetero Drugs Ltd Krystaliczna zasada alfuzosyny
US20070049756A1 (en) * 2005-08-30 2007-03-01 Anumula Raghupathi R Alfuzosin hydrochloride polymorphs
WO2007069050A2 (en) * 2005-12-16 2007-06-21 Wockhardt Ltd. Processes for the preparation of alfuzosin
US20100092556A1 (en) * 2006-12-11 2010-04-15 Kristin Arnold Alfuzosin formulations, methods of making, and methods of use
US20080160081A1 (en) * 2006-12-11 2008-07-03 Mutual Pharmaceutical Company, Inc. Alfuzosin formulations, methods of making, and methods of use
WO2008114272A2 (en) * 2007-03-22 2008-09-25 Cadila Healthcare Limited Process for preparing alpuzosin and crystalline alfuzosin hydrochloride
EP2152697A2 (de) 2007-05-04 2010-02-17 Actavis Group PTC EHF Verfahren zur herstellung von alfuzosin und salzen daraus
KR20100044239A (ko) * 2007-08-02 2010-04-29 시플라 리미티드 알푸조신 염산염의 제조방법
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
WO2010083360A2 (en) * 2009-01-16 2010-07-22 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
CN114674967B (zh) * 2022-03-25 2022-10-04 邦恩泰(山东)生物医药科技集团股份有限公司 N-甲基-n′-四氢呋喃甲酰基丙二胺草酸盐有关物质的检测方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1591490A (en) * 1977-08-04 1981-06-24 Abbott Lab 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-tetrahydrofuroyl)piperazine hydrochloride dihydrate
FR2421888A1 (fr) * 1978-02-06 1979-11-02 Synthelabo Amides d'alkylene-diamines et leur application en therapeutique
FI79107C (fi) * 1984-06-25 1989-11-10 Orion Yhtymae Oy Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.
US4925837A (en) * 1984-09-14 1990-05-15 Synthelabo Pharmaceutical compositions
FR2582513B1 (fr) * 1985-05-28 1988-08-05 Synthelabo Compositions pharmaceutiques contenant de l'alfuzosine
US5294615A (en) * 1993-04-29 1994-03-15 Abbott Laboratories Terazosin polymorph and pharmaceutical composition

Also Published As

Publication number Publication date
JPH07206857A (ja) 1995-08-08
EP0663398A1 (de) 1995-07-19
KR100329156B1 (ko) 2002-11-22
US5545738A (en) 1996-08-13
ATE190614T1 (de) 2000-04-15
EP0663398B1 (de) 2000-03-15
KR950017992A (ko) 1995-07-22
DE69423459D1 (de) 2000-04-20

Similar Documents

Publication Publication Date Title
DE69423459D1 (de) Dihydrat des N-(4-Amino-6,7-dimethoxychinazol-2-yl)-N-methyl-N'-(tetrahydrofuroyl-2)-propylendiamin Hydrochlorids(=Alfuzosin Hydrochlorid Dihydrat) und ein Verfahren zur Herstellung
DE69915004D1 (de) 5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
FI941378A0 (fi) Bentsimidatsoliyhdisteitä, niiden käyttö ja valmistus
DE69034202D1 (de) Zwischenprodukte zur Herstellung von non-peptiden retroviralproteasehemmenden Verbindungen
ATE163012T1 (de) N-substituierte 4-pyrimidinamine und - pyrimidindiamine, verfahren zu ihrer herstellung und ihre anwendung als arzneimittel
ATE410412T1 (de) Oxopyrrolidin verbindungen, verfahren zur herstellung dieser verbindungen und deren verwendung zur herstellung von levetiracetam und analogen
DE59309819D1 (de) Verwendung von 2-(N-(2-Aminoethyl)amino)-essigsäure-derivaten zur Behandlung von Erkrankungen, die durch die nichtenzymatische Glykosylierung bedingt sind
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
DK26289A (da) Anvendelse af 1,4-disubstitueret piperidinyl til fremstilling af et farmaceutisk praeparat til behandling af insomnia
HUT57773A (en) Process for produicng n-(aminocarbonyl)-carbamates related to physostigmine, as well as pharmaceutical compositions comprising such compounds
ES2194102T3 (es) Nuevas n-(2,4-dioxo-2,3,4,5-tetrahidro-1h-1,5-benzodiazepin-3-il)-3-amidas.
LV11689A (lv) 4-Ú(2-benzotiazolil)metilamino¾-alfa-Ú(3,4-difluorfenoksi)metil¾-1-piperidinetanols
DE69005984D1 (de) 2-Hydroxy-3-phenoxypropylaminoverbindungen.
NO910904D0 (no) Fremgangsmaate for fremstilling av en substituert aminforbindelse.
ATE245147T1 (de) Substituierte aminochinazolinon (thion) derivate
DE60104986D1 (de) Xanthinderivate, zwischenprodukte und verwendung zur behandlung von osteoporosis
BR0116721A (pt) Processo para a preparação de (±)-trans-4-p-fluorofenil-3-hidroximetil-1-metilpiperi dina
DE59009951D1 (de) Verfahren zur Herstellung von Zwischenprodukten und zur Synthese von N-(2-Hydroxyethyl)-2-hydroxymethyl-3,4,5-trihydroxypiperidine.
DK0410278T3 (da) Reninhæmmende aminooligohydroxyderivater
DE69107561D1 (de) Verfahren zur Herstellung von 4-Methylsulfonylbenzoesäurederivate und Zwischenprodukte.
DE69229017T2 (de) Glyceraldehyd-3-pentanid und Verfahren zu ihrer Herstellung
FI924769A (fi) Foerfarande foer framstaellning av substituerade indoler
DE59407547D1 (de) Verfahren zur Herstellung von 2-substituierten 5-Chlorimidazol-4-carbaldehyden
DE59406704D1 (de) Verfahren zur Herstellung von gegebenenfalls 2-substituierten 5-Chlorimidazol-4-carbaldehyden
DE3887611T2 (de) Butensäure-Amide, deren Salze, diese enthaltende pharmazeutische Zusammensetzungen und Verfahren zu deren Herstellung.

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SANOFI-AVENTIS, PARIS, FR

8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 663398

Country of ref document: EP

Representative=s name: TER MEER STEINMEISTER & PARTNER GBR PATENTANWA, DE